KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Abbott Laboratories (ABT) EBT Margin (2016 - 2025)

Abbott Laboratories (ABT) has disclosed EBT Margin for 17 consecutive years, with 20.58% as the latest value for Q4 2025.

  • Quarterly EBT Margin rose 208.0% to 20.58% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 19.1% through Dec 2025, up 238.0% year-over-year, with the annual reading at 19.1% for FY2025, 238.0% up from the prior year.
  • EBT Margin hit 20.58% in Q4 2025 for Abbott Laboratories, up from 19.17% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 24.18% in Q1 2022 to a low of 13.08% in Q4 2022.
  • Historically, EBT Margin has averaged 18.01% across 5 years, with a median of 17.88% in 2023.
  • Biggest five-year swings in EBT Margin: skyrocketed 1135bps in 2021 and later plummeted -815bps in 2023.
  • Year by year, EBT Margin stood at 20.29% in 2021, then plummeted by -36bps to 13.08% in 2022, then surged by 34bps to 17.53% in 2023, then increased by 6bps to 18.5% in 2024, then grew by 11bps to 20.58% in 2025.
  • Business Quant data shows EBT Margin for ABT at 20.58% in Q4 2025, 19.17% in Q3 2025, and 19.3% in Q2 2025.